Literature DB >> 24791833

SuHx rat model: partly reversible pulmonary hypertension and progressive intima obstruction.

Michiel Alexander de Raaf1, Ingrid Schalij1, Jose Gomez-Arroyo2, Nina Rol1, Chris Happé1, Frances S de Man3, Anton Vonk-Noordegraaf1, Nico Westerhof3, Norbert F Voelkel4, Harm Jan Bogaard5.   

Abstract

The SU5416 combined with hypoxia (SuHx) rat model features angio-obliterative pulmonary hypertension resembling human pulmonary arterial hypertension. Despite increasing use of this model, a comprehensive haemodynamic characterisation in conscious rats has not been reported. We used telemetry to characterise haemodynamic responses in SuHx rats and associated these with serial histology. Right ventricular systolic pressure (RVSP) increased to a mean±sd of 106±7 mmHg in response to SuHx and decreased but remained elevated at 72±8 mmHg upon return to normoxia. Hypoxia-only exposed rats showed a similar initial increase in RVSP, a lower maximum RVSP and near-normalisation of RVSP during subsequent normoxia. Progressive vascular remodelling consisted of a four-fold increase in intima thickness, while only minimal changes in media thickness were found. The circadian range in RVSP provided an accurate longitudinal estimate of vascular remodelling. In conclusion, in SuHx rats, re-exposure to normoxia leads to a partial decrease in pulmonary artery pressure, with persisting hypertension and pulmonary vascular remodelling characterised by progressive intima obstruction. © ERS 2014.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24791833     DOI: 10.1183/09031936.00204813

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  30 in total

Review 1.  Drug abuse and HIV-related pulmonary hypertension: double hit injury.

Authors:  Zachery J Harter; Stuti Agarwal; Pranjali Dalvi; Norbert F Voelkel; Navneet K Dhillon
Journal:  AIDS       Date:  2018-11-28       Impact factor: 4.177

2.  Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor Sacubitril/Valsartan.

Authors:  Richard T Clements; Alexander Vang; Ana Fernandez-Nicolas; Nouaying R Kue; Thomas J Mancini; Alan R Morrison; Krishna Mallem; Danielle J McCullough; Gaurav Choudhary
Journal:  Circ Heart Fail       Date:  2019-11-11       Impact factor: 8.790

3.  Shunt Surgery, Right Heart Catheterization, and Vascular Morphometry in a Rat Model for Flow-induced Pulmonary Arterial Hypertension.

Authors:  Diederik E van der Feen; Michel Weij; Annemieke Smit-van Oosten; Lysanne M Jorna; Quint A J Hagdorn; Beatrijs Bartelds; Rolf M F Berger
Journal:  J Vis Exp       Date:  2017-02-11       Impact factor: 1.355

Review 4.  Mechanisms of pulmonary vascular dysfunction in pulmonary hypertension and implications for novel therapies.

Authors:  Helen Christou; Raouf A Khalil
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-02-25       Impact factor: 4.733

5.  A wrinkle in time: circadian biology in pulmonary vascular health and disease.

Authors:  Andrew J Bryant; Elnaz Ebrahimi; Amy Nguyen; Christopher A Wolff; Michelle L Gumz; Andrew C Liu; Karyn A Esser
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2021-12-01       Impact factor: 5.464

6.  Impaired Pulmonary Arterial Vasoconstriction and Nitric Oxide-Mediated Relaxation Underlie Severe Pulmonary Hypertension in the Sugen-Hypoxia Rat Model.

Authors:  Helen Christou; Hannes Hudalla; Zoe Michael; Evgenia J Filatava; Jun Li; Minglin Zhu; Jose S Possomato-Vieira; Carlos Dias-Junior; Stella Kourembanas; Raouf A Khalil
Journal:  J Pharmacol Exp Ther       Date:  2017-12-06       Impact factor: 4.030

7.  Histone deacetylase inhibition with trichostatin A does not reverse severe angioproliferative pulmonary hypertension in rats (2013 Grover Conference series).

Authors:  Michiel Alexander De Raaf; Aysar Al Hussaini; Jose Gomez-Arroyo; Donatas Kraskaukas; Daniela Farkas; Chris Happé; Norbert F Voelkel; Harm Jan Bogaard
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

8.  Delayed Microvascular Shear Adaptation in Pulmonary Arterial Hypertension. Role of Platelet Endothelial Cell Adhesion Molecule-1 Cleavage.

Authors:  Robert Szulcek; Chris M Happé; Nina Rol; Ruud D Fontijn; Chris Dickhoff; Koen J Hartemink; Katrien Grünberg; Ly Tu; Wim Timens; George D Nossent; Marinus A Paul; Thomas A Leyen; Anton J Horrevoets; Frances S de Man; Christophe Guignabert; Paul B Yu; Anton Vonk-Noordegraaf; Geerten P van Nieuw Amerongen; Harm J Bogaard
Journal:  Am J Respir Crit Care Med       Date:  2016-06-15       Impact factor: 21.405

9.  NADPH oxidase-mediated endothelial injury in HIV- and opioid-induced pulmonary arterial hypertension.

Authors:  Stuti Agarwal; Himanshu Sharma; Ling Chen; Navneet K Dhillon
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-04-01       Impact factor: 5.464

10.  Naringin Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension Through Endothelial-To-Mesenchymal Transition Inhibition.

Authors:  Yonghui Wu; Changhong Cai; Yijia Xiang; Huan Zhao; Lingchun Lv; Chunlai Zeng
Journal:  Front Pharmacol       Date:  2021-07-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.